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ABSTRACT
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis 
(XDR-TB) continue to challenge physicians and public health specialists. Global treatment 
outcomes continue to be unsatisfactory, positive outcomes being achieved in only 54% 
of patients. Overall outcomes are even worse in patients infected with highly resistant 
strains. Treating MDR-/XDR-TB is difficult because of frequent adverse events, the long 
duration of drug regimens, the high costs of second-line drugs, chronic post-infectious 
sequelae, and loss of organ function. Ongoing research efforts (studies and trials) have 
various aims: increasing the rates of treatment success; understanding the potentialities 
of new and repurposed drugs; shortening the treatment duration; and reducing the 
rates of adverse events. It is hoped that better access to rapid diagnostics, increased 
awareness, and treatments that are more effective will reduce the rate of complications 
and of lung function impairment. This article aims to discuss the management of severe 
tuberculosis (defined as that which is potentially life threatening, requiring higher levels 
of care) and its sequelae, from intensive care to the postoperative period, rehabilitation, 
and recovery. We also discuss the nonpharmacological interventions available to manage 
chronic sequelae and improve patient quality of life. Because the majority of MDR-/
XDR-TB cases evolve to lung function impairment (typically obstructive but occasionally 
restrictive), impaired quality of life, and low performance status (as measured by 
walk tests or other metrics), other interventions (e.g., smoking cessation, pulmonary 
rehabilitation, vaccination/prevention of secondary bacterial infections/exacerbations, 
complemented by psychological and nutritional support) are required. 
Keywords: Extensively drug-resistant tuberculosis; Tuberculosis, multidrug-resistant; 
Critical care; Smoking cessation.
Managing severe tuberculosis and its 
sequelae: from intensive care to surgery 
and rehabilitation
Simon Tiberi1,2,a, Marcela Muñoz Torrico3,b, Ananna Rahman1,c,  
Maria Krutikov1,d, Dina Visca4,e, Denise Rossato Silva5,f, Heinke Kunst2,g, 
Giovanni Battista Migliori4,h
Correspondence to: 
Giovanni Battista Migliori. Istituti Clinici Scientifici Maugeri IRCCS, Via Roncaccio 16, 21049, Tradate, Italia. 
Tel.: 39 0331 829404. E-mail: giovannibattista.migliori@icsmaugeri
Financial support: None.
INTRODUCTION
Tuberculosis, also known as the “white plague”, 
continues to be a public health priority. In its most 
recent Global Tuberculosis Report,(1) the World Health 
Organization (WHO) estimated that 1.6 million 
tuberculosis-related deaths occurred in 2017. In 
addition, half a million cases of multidrug-resistant 
tuberculosis (MDR-TB, defined as infection with a strain 
of Mycobacterium tuberculosis that is resistant to at least 
isoniazid and rifampin) have been reported worldwide, and 
8.5% of those were cases of extensively drug-resistant 
tuberculosis (XDR-TB, defined as infection with an MDR-TB 
strain that is also resistant to fluoroquinolones and at 
least one second-line injectable drug).
Although recent studies have demonstrated that higher 
tuberculosis treatment success rates are achievable,(2) 
the overall rate of treatment success among MDR-TB 
patients worldwide is currently below 55%, treatment 
success rates being lower than 20% in difficult-to-treat 
cases in which the resistance profile is XDR or beyond. (1,3) 
Drug abuse, smoking, and alcohol dependence can 
further aggravate outcomes.(4-9) Treating MDR-/XDR-TB 
is challenging because of frequent adverse events, the 
lengthy duration of costly second-line drug regimens, and 
the fact that patient management is often onerous,(4-9) 
not to mention the financial and social impact of the 
illness on the affected individuals and their families. 
There are ongoing research efforts (studies and trials) 
with a variety of aims(1,4,10-12): increasing treatment 
success rates; understanding the potentialities of new 
and repurposed drugs; shortening the treatment duration; 
and reducing the rate of adverse events.
This paper aims to provide an overview of the 
management of tuberculosis in the intensive care setting, 
the role of adjunctive surgery, and the rehabilitation of 
patients affected by tuberculosis. The manuscript can 
be read in its entirety—as a pathway from admission to 
intensive care, surgical intervention (when indicated), 
rehabilitation, and recovery—or in its separate units. 
An additional aim is to remind the reader that patients 
1. Barts Health NHS Trust, Royal London 
Hospital, Division of Infection, London, 
United Kingdom. 
2. Blizard Institute, Barts and the London 
School of Medicine and Dentistry, 
Centre for Primary Care and Public 
Health, London, United Kingdom. 
3. Clínica de Tuberculosis, Instituto 
Nacional de Enfermedades 
Respiratorias, Ciudad de México, DF, 
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are seldom entirely back to their former selves when 
they have completed the prescribed drug therapy 
regimen, because a long rehabilitation/convalescence 
phase typically ensues. Therefore, the importance of 
nonpharmacological interventions (e.g., pulmonary 
rehabilitation with supervised exercises, chest/
breathing exercises, expectoration techniques, 
vaccination, and smoking cessation) should be 
explored in surviving patients in order to improve the 
functional residual capacity, limit end organ damage, 
and minimize the chronic sequelae of tuberculosis.
METHODS
We searched for articles in English, Spanish, or 
Portuguese, published between November 1, 2014 
and June 1, 2018, on Google, Google Scholar, PubMed, 
and ClinicalTrials.gov. The following search terms were 
used: “tuberculosis”; “MDR-TB”; “XDR-TB”; “severe 
tuberculosis”; “intensive care and tuberculosis”; and 
“tuberculosis and surgery”. Targeted searches were 
also performed for articles dealing with pulmonary 
rehabilitation, smoking cessation, or quality of 
life. The WHO definitions are used throughout the 
manuscript. (13,14)
TUBERCULOSIS IN THE INTENSIVE CARE 
SETTING
Despite the success of curative therapy, a significant 
proportion of tuberculosis patients are hospitalized 
every year, 1-3% requiring admission to the ICU for 
close monitoring or organ support.(15) The indications for 
ICU admission include the following: complications of 
tuberculosis (including respiratory failure and conditions 
requiring surgical interventions, such as hemorrhage, 
pneumothorax, and pleural effusion); the severe 
forms of tuberculosis (e.g., tuberculous meningitis 
with impaired consciousness requiring intubation) 
or severe clinical manifestations of comorbidities 
(e.g., liver disease, renal disease, and uncontrolled 
diabetes); and life-threatening events resulting from 
adverse reactions to antituberculosis drugs (e.g. organ 
failure, severe seizures, and anaphylaxis).
The most common reasons for admission to the 
ICU are acute respiratory failure (in > 90%), septic 
shock (in 20-34%), and multiorgan failure (in 
34-44%).(15-17) Other causes include renal failure 
(in 10%), neurological disorders (in 20%), and 
meningeal tuberculosis (in 20%).(15,17) In addition, 
patients with tuberculosis can be admitted to the 
ICU for extrapulmonary manifestations of the 
disease, including spinal, pericardial, bone marrow, 
hematological, and genitourinary disease,(17) as well 
as for bacterial coinfections, antituberculosis drug 
toxicity, thromboembolic complications, or pulmonary 
hemorrhage.(16-19) Patients with tuberculosis can also 
become critically ill because of factors indirectly related 
to their tuberculosis, such as diabetic ketoacidosis, 
alcohol withdrawal, and electrolyte imbalances.(17,18) 
ICU admission due to HIV coinfection occurs in 68.7% 
of tuberculosis patients in high-incidence countries 
and in 40% of those in low-incidence countries.(15)
Most tuberculosis patients who are admitted to the 
ICU have an established diagnosis of tuberculosis, 
although there are some who do not present with the 
typical clinical or radiological signs of tuberculosis. 
In such cases, a high index of suspicion is required 
in order to make the diagnosis. A diagnosis of 
tuberculosis should be suspected in patients who are 
contacts of tuberculosis patients and in those who 
have risk factors for the disease.(20) The possibility of 
reactivation of latent tuberculosis infection due to stress 
or immunosuppression should also be considered.(21)
The management of tuberculosis in the ICU is 
daunting given the frequent complexity and poor 
outcomes associated with the disease. For cases 
of infection with drug-susceptible strains of M. 
tuberculosis, the WHO guidelines recommend standard 
quadruple therapy with rifampin, isoniazid, ethambutol, 
and pyrazinamide. (22) It is also necessary to seek 
advice from clinicians with expertise in managing 
the treatment of MDR-TB, XDR-TB, and tuberculosis 
involving coinfection with other pathogens.(23,24)
The mode of delivery of antituberculosis drugs in the 
ICU setting depends mainly on intestinal absorption, 
which can be delayed or altered due to gastroparesis, 
intestinal paralysis, enteral nutrition, edema due 
to hypoalbuminemia, and critical illness-associated 
changes in the gut microbiota.(25) In addition, the 
pharmacokinetics of antituberculosis drugs can be 
altered during critical illness.(26) In an observational case 
series of critically ill tuberculosis patients who received 
quadruple therapy administered via a nasogastric 
tube, therapeutic blood levels were achieved in only 
30%. (27) Although rifampin is available in an intravenous 
formulation in some countries (not currently in Brazil), 
other antituberculosis drugs generally are not. In 
most cases, antituberculosis drugs are administered 
parenterally.(20,25) Furthermore, although some drugs 
can adhere to the nasogastric tube (e.g., rifampin), 
they can be administered intravenously to achieve and 
maintain therapeutic blood levels, which makes them 
more efficacious.(25) The fact that first-line drugs are 
rarely available in an intravenous formulation results 
in the widespread use of second-line drugs such as 
fluoroquinolones and aminoglycosides.
In the ICU, corticosteroids are frequently administered 
in conjunction with antituberculosis drugs. There is 
evidence that adjuvant treatment with corticosteroids 
reduces mortality in non-HIV-infected patients with 
tuberculous meningitis or pericarditis.(28) In a recent 
meta-analysis, corticosteroids were reported to reduce 
mortality in all forms of tuberculosis, with a more 
pronounced effect in patients with a severe form of 
the disease, such as miliary tuberculosis.(29,30)
Due to the variable pharmacokinetics and 
pharmacodynamics of antituberculosis drugs, it is 
essential to remain vigilant regarding drug toxicity 
and interactions, by carrying out active drug safety 
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monitoring. This is especially true for rifampin, which 
will interact with many drugs used in the ICU setting 
because of its effect of inducing cytochrome P450.(21,25)
Among tuberculosis patients requiring admission to 
the ICU, mortality is > 50%, ranging from 20% to 
70%. (15,17,31,32) Mortality is even higher among patients 
on mechanical ventilation, one study reporting a 
mortality rate of 80% in tuberculosis patients with 
ARDS who required mechanical ventilation.(15) Risk 
factors for mortality include ARDS, multiorgan failure, 
sepsis, mechanical ventilation, renal replacement 
therapy, a high Acute Physiology and Chronic 
Health Evaluation II score, and a high Sequential 
Organ Failure Assessment score.(17,24,31,32) We find 
it interesting that diabetes and HIV have not been 
associated with increased mortality, possibly because 
they are overshadowed by the aforementioned risk 
factors.(17,24,25,31,32)
Tuberculosis patients admitted to the ICU are a 
heterogeneous population, and the complexities of 
tuberculosis exacerbate that heterogeneity. Mortality 
remains high, and the disease is associated with 
considerable morbidity. Most of the studies on the 
topic have been case reports and retrospective 
analyses. There is therefore a need for prospective 
studies in this area, especially regarding rapid 
diagnostic methods, novel treatments (including the 
use of immunomodulatory agents and host-directed 
therapies), and intensification of tuberculosis 
treatment.
ADJUNCTIVE SURGERY IN THE 
MANAGEMENT OF TUBERCULOSIS
Historically (before the development of 
antituberculosis drugs), surgery was the only treatment 
available for tuberculosis. Surgical procedures could 
be grouped into those that artificially collapse the 
lung and those in which the affected tissue is excised. 
Procedures in the first group include lung collapse by 
artificial induction of pneumothorax and thoracoplasty 
involving the removal of a rib or ribs (to collapse the 
lung cavity). (33) Procedures in the second group are 
more widely accepted by the medical community 
and include the following(33): wedge resection, first 
described by Tuffler in 1891; pneumonectomy, first 
described by Lilienthal in 1933; and lobectomy, first 
described by Freedlander in 1935. The advent of 
combination therapy for tuberculosis, in 1952, allowed 
the infection to be eradicated through noninvasive 
means and subsequently reduced the number of 
operations performed in the affected patients.(33-35)
Over the last few decades, the emergence of drug-
resistant M. tuberculosis strains has reduced success 
rates for treatment with drug therapy alone and has 
increased the number of tuberculosis patients who 
require surgery. Scarring and fibrous tissue can protect 
bacteria from the host immune response, allowing 
them to continue to replicate, thus preventing the 
eradication of infection and driving the development 
of drug-resistant mutations. Surgical removal of the 
affected tissue allows the antimicrobial therapy to 
penetrate the remaining lung more effectively and 
eradicates the foci of bacillary growth.(36) The largest 
case series to date was published in 2018 by Giller 
at al.,(37) who documented 5,599 thoracic surgical 
procedures in tuberculosis patients treated in Russia 
during a 17-year period. The authors reported an 
overall mortality rate of 0.1%, also reporting treatment 
success rates of 93.0% and 92.1% in patients with 
MDR-TB and XDR-TB, respectively.
Most surgical procedures in tuberculosis patients 
have been performed on a case-by-case basis, and 
current evidence is therefore from observational 
studies with a paucity of reliable data on the 
indications, individual procedure outcomes, and cure 
rates related to surgery used in combination with an 
antituberculosis treatment regimen. Consequently, 
the WHO issued a consensus statement in 2014,(34) 
followed by an update of the MDR-TB treatment 
guidelines in 2016,(38) with a section focusing on the 
role of surgery in tuberculosis treatment. The WHO 
consensus statement referenced a 2013 systematic 
review conducted by Marrone et al.,(39) who found 
the overall success rates of pulmonary resection 
in combination with antituberculosis therapy to be 
88-92%, with a reduction in overall all-cause mortality, 
when that treatment combination is performed in 
appropriate settings on carefully selected patients. 
Evidence from a study conducted in Peru suggested 
that the addition of surgery can reduce the overall cost 
of MDR-TB treatment because it allows the duration 
of the treatment regimen to be shortened.(40)
The indications for surgery in patients with 
tuberculosis, as listed by Dara et al.,(35) are divided 
into three main sections: emergency—profuse lung 
hemorrhage and spontaneous tension pneumothorax; 
urgent—irreversible progression of disease despite 
tuberculosis therapy and recurrent or recalcitrant 
hemoptysis; and elective—localized cavities with 
persistent smear/culture positivity for M. tuberculosis 
after 4-6 months of directly observed antituberculosis 
therapy, MDR-/XDR-TB in which antituberculosis 
treatment has failed, and complications of tuberculosis 
requiring surgical intervention, including pneumothorax 
(which can be spontaneous), pyopneumothorax, 
pleural emphysema (with or without bronchopleural 
fistula), and aspergilloma. The 2014 WHO consensus 
statement stipulated that patients should receive at 
least 4-6 months of an appropriate antituberculosis 
regimen before surgery and their suitability as 
surgical candidates should be assessed, ensuring 
adequate postoperative pulmonary functional residual 
capacity. (34) The procedure should be performed at a 
center with adequate facilities and by a highly-skilled 
surgeon with experience in tuberculosis. Because the 
mortality rate reported for lobectomy (2-3%) is lower 
than that reported for pneumonectomy (7-8%), the 
former is the preferred procedure. Postoperatively, 
patients should continue to receive antituberculosis 
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therapy for at least 4 months, depending on the 
characteristics of the underlying disease. 
The most recent WHO MDR-TB guidelines, updated in 
2016,(38) also recommend elective partial lung resection 
(lobectomy or wedge resection) in conjunction with 
an appropriate MDR-TB treatment regimen. That 
recommendation is based on three meta-analyses 
that collectively found treatment outcomes to be 
significantly better in patients treated with the 
combination of surgery and drug therapy than in those 
treated with drug therapy alone (81.9% vs. 59.7%; 
OR = 2.62, 95% CI: 1.94-3.54).(41-43) However, the 
guidelines also stressed the superiority of partial lung 
resection over pneumonectomy in achieving a cure, 
as well as in improving overall outcomes. 
We believe that there is a role for surgery in the 
treatment of complicated tuberculosis infection, 
especially infection with drug-resistant strains, with the 
potential to shorten treatment duration and improve 
outcomes. Better retrospective data surveillance is 
needed in order to inform clinicians of the indications 
for surgery, the optimal surgical procedures, and their 
potential outcomes. 
REHABILITATION
The sequelae of pulmonary tuberculosis (PTB) can 
cause significant pulmonary impairment and morbidity, 
particularly in young adults. Therefore, the completion 
of tuberculosis treatment might mark the beginning 
of a chronic respiratory disease. Unfortunately, there 
have been only a few studies addressing this issue, 
and most of them have assessed respiratory function 
only through the use of simple spirometry.
A history of PTB is undoubtedly related to lung function 
impairment and lung function test abnormalities.(44,45) 
Lung damage can occur in the bronchial airway, the 
lung parenchyma, or both. A number of population-
based studies using spirometry and bronchodilator 
tests have demonstrated that individuals with PTB 
have airflow obstruction that does not respond to 
bronchodilator administration(46,47) Therefore, PTB is 
a well-recognized risk factor for the development of 
COPD in young adults with no history of smoking.(48) 
PTB has also been described as a frequent cause of 
bronchiectasis and tracheobronchial stenosis. At the 
parenchymal level, the severity can be quite variable: 
single or multiple cavities can be seen, with or without 
areas of scarring; or there can be areas of complete 
lung destruction. The presence of lung destruction 
confers a poor prognosis, especially if the destruction 
is extensive.(49) Such damage can also involve the 
pleura and promote the development of diffuse pleural 
fibrosis, resulting in restrictive lung disease. In addition 
to the variety of pulmonary abnormalities caused by 
PTB sequelae, the remaining areas of damaged lung 
increase the risk of further complications such as 
the development of aspergilloma and infection with 
nontuberculous mycobacteria.
There is still a need to carry out more studies to 
understand the pathophysiology of PTB sequelae, 
thoroughly assessing its impact on pulmonary function 
and patient quality of life. However, it is clear that such 
sequelae cause pulmonary impairment and contribute 
significantly to the burden of chronic respiratory 
diseases worldwide.(44,50) Therefore, it is necessary 
to perform a complete pulmonary evaluation (with 
imaging examinations and pulmonary function tests) 
at the end of treatment in PTB patients, as is done 
in patients with other chronic respiratory diseases, 
in order to improve their quality of life.
As a result of the lung destruction due to PTB, 
affected patients frequently have persistent respiratory 
symptoms, which limit their activities of daily living 
and reduce their quality of life.(51,52) Therefore, 
pulmonary rehabilitation at the end treatment is an 
appropriate measure. Pulmonary rehabilitation has 
been proven to improve the perception of dyspnea, 
exercise tolerance, and health-related quality of life 
in patients with COPD or other chronic respiratory 
diseases.(53,54) Although there are few data regarding its 
use in patients with PTB sequelae, some studies have 
suggested that it is beneficial for such patients.(55-59) 
It might even be possible to adapt the rehabilitation 
program to specific circumstances, so that it is made 
accessible to individuals in low-resource settings. (56) In 
addition to its role in the management of PTB sequelae, 
pulmonary rehabilitation can be a useful tool in the 
multidisciplinary management of surgical candidates, 
as well as in patients with severe tuberculosis who 
require ICU admission and long hospital stays, in order 
to decrease the risk of further respiratory complications 
and to prevent or reverse muscle atrophy.(60,61) The 
indications for pulmonary rehabilitation can include 
evidence of lung damage (resulting in obstructive or 
restrictive lung disease), exercise-induced oxygen 
desaturation, and impaired quality of life.
A recent review of the available literature on chronic 
sequelae after the completion of antituberculosis 
treatment(44) focused specifically on sequelae and 
their functional evaluation, as well as on lung 
destruction and the pulmonary interventions available 
(e.g., long-term oxygen therapy, ventilation, and 
respiratory therapy). The authors recommended 
that future studies not only evaluate the outcomes 
of antituberculosis drug therapy but also include 
a complete description of the pathophysiological 
status of the patients, including radiological aspects 
(Figure 1); spirometry findings and bronchodilator 
response (Figure 2); assessment of lung volumes by 
plethysmography (Figure 3); DLCO (Figure 4); arterial 
blood gases; six-minute walk distance; and quality of 
life (evaluated with validated tools such as the Saint 
George’s Respiratory Questionnaire). If rehabilitation 
programs are implemented, it is essential to collect 
information on pre- and post-rehabilitation outcomes, 
as well as on the costs of the intervention.
Cigarette smoking is a definite risk factor for various 
pulmonary infections, including tuberculosis. A number 
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Figure 1. Pre- and post-treatment X-rays of a patient with multidrug-resistant tuberculosis, showing sequelae on the 
left side. 
Figure 2. Spirometry findings in a patient with severe multidrug-resistant tuberculosis, at the end of antituberculosis 
treatment.
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of population-based studies have shown that smoking 
increases the risk of developing latent or active 
tuberculosis.(62) In addition, smoking has been linked to 
adverse outcomes (treatment failure or death), relapse, 
and an increased risk of developing drug-resistant 
tuberculosis,(63) as well as to worsening of the initial 
pattern of drug resistance. A coherent smoking cessation 
approach, including a wide range of interventions (e.g., 
psychosocial and pharmacological interventions), has 
been proven to increase the treatment success rates 
in tuberculosis patients while decreasing the risk of 
further pulmonary complications.(64-66) Therefore, the 
WHO recommends integrating early and effective 
smoking cessation measures, starting at the primary 
health care level, into tuberculosis control plans.(67) 
Because of the similar risk posed by alcohol abuse, 
comparable interventions have also been recommended 
for individuals with alcohol dependence.(68,69)
FINAL CONSIDERATIONS
In conclusion, the existence of effective therapy 
notwithstanding, tuberculosis is frequently encountered 
in the ICU, and the disease represents a distinct 
challenge with poor outcomes. The emergence of 
drug-resistant strains of M. tuberculosis has recently 
restored thoracic surgery to a prominent position 
among interventions designed to combat tuberculosis. 
When combined with effective drug therapy, surgery 
has been associated with favorable outcomes in cases 
of MDR-/XDR-TB. There is recent evidence that chronic 
post-infectious sequelae of tuberculosis are common 
even after effective therapy, more so after surgery. (44) 
That suggests that the majority of tuberculosis cases 
will evolve to lung function impairment (typically 
obstructive but occasionally restrictive), impaired 
quality of life, and reduced performance status (as 
measured by walk tests or other metrics). Therefore, 
other interventions—pulmonary rehabilitation (including 
supervised exercise, chest/breathing exercises, and 
expectoration), smoking cessation therapy, and 
prevention (of secondary bacterial infections and 
exacerbations), complemented by psychological and 
nutritional support—are required in order to protect or 
restore functional residual capacity, thereby improving 
quality of life and slowing the progression to frailty.
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Figure 3. Plethysmography showing air trapping in a patient with multidrug-resistant tuberculosis, after the completion 
of antituberculosis treatment. 
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Figure 4. Severe (39%) reduction in DLCO in a patient with multidrug-resistant tuberculosis.
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